<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Clinical Management &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/clinical-management/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 09 Jan 2026 20:51:42 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Clinical Management &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Revised Insights on Freezing of Gait Explained</title>
		<link>https://bioengineer.org/revised-insights-on-freezing-of-gait-explained/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 09 Jan 2026 20:51:21 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Clinical Management]]></category>
		<category><![CDATA[Dopamine Response]]></category>
		<category><![CDATA[Freezing of Gait]]></category>
		<category><![CDATA[Gait Classification]]></category>
		<category><![CDATA[Parkinson’s disease]]></category>
		<guid isPermaLink="false">https://bioengineer.org/revised-insights-on-freezing-of-gait-explained/</guid>

					<description><![CDATA[Freezing of gait (FOG) is a prevalent yet complex phenomenon among individuals diagnosed with Parkinson’s Disease (PD). Characterized by an inability to initiate movement, it often interrupts the gait cycle, leading to significant mobility challenges and heightened fall risk. In recent years, research has sought to categorize FOG based on a variety of clinical and [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">315430</post-id>	</item>
		<item>
		<title>Navigating Melanoma Immunotherapy in Compromised Immune Systems</title>
		<link>https://bioengineer.org/navigating-melanoma-immunotherapy-in-compromised-immune-systems/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 30 Dec 2025 06:57:32 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Clinical Management]]></category>
		<category><![CDATA[Compromised Immune Systems]]></category>
		<category><![CDATA[immune-related adverse events]]></category>
		<category><![CDATA[Melanoma Immunotherapy]]></category>
		<category><![CDATA[personalized medicine]]></category>
		<guid isPermaLink="false">https://bioengineer.org/navigating-melanoma-immunotherapy-in-compromised-immune-systems/</guid>

					<description><![CDATA[Immunotherapy has revolutionized the treatment landscape for melanoma, particularly in the last decade. However, as the potential for these innovative therapies continues to expand, researchers are increasingly focused on understanding the unique challenges faced by patients with altered immune systems. These patients, who may have underlying conditions such as autoimmune diseases, organ transplants, or those [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">312280</post-id>	</item>
	</channel>
</rss>
